RESUMEN
Heparin-induced thrombocytopenia (HIT) is immune-mediated. It occurs more frequently with unfractionated heparin (UFH) than with low molecular weight heparins (LMWH). It is associated with thromboembolic rather than hemorrhagic events, as opposed to thrombocytopenia of other etiologies. The key in therapy is the cessation of heparin and the start of another anticoagulant. We report a 58 years old female with HIT secondary to the use of Enoxaparin who was successfully managed with Rivaroxaban. Our goal is to report a novel therapy and provide the evidence that supports its use.
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Trombocitopenia/inducido químicamente , Trombocitopenia/tratamiento farmacológico , Heparina/uso terapéutico , Inhibidores del Factor Xa/uso terapéutico , Rivaroxabán/uso terapéutico , Anticoagulantes/efectos adversos , Factores de Riesgo , Resultado del Tratamiento , Trombosis de la Vena/etiología , Trombosis de la Vena/prevención & controlRESUMEN
Heparin-induced thrombocytopenia (HIT) is immune-mediated. It occurs more frequently with unfractionated heparin (UFH) than with low molecular weight heparins (LMWH). It is associated with thromboembolic rather than hemorrhagic events, as opposed to thrombocytopenia of other etiologies. The key in therapy is the cessation of heparin and the start of another anticoagulant. We report a 58 years old female with HIT secondary to the use of Enoxaparin who was successfully managed with Rivaroxaban. Our goal is to report a novel therapy and provide the evidence that supports its use.